Phase I Trial Of Intrahepatic Infusion Of 2nd Generation Designer T Cells For Cea-Expressing Liver Metastases

Trial Profile

Phase I Trial Of Intrahepatic Infusion Of 2nd Generation Designer T Cells For Cea-Expressing Liver Metastases

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs CAR-T CEA therapy (Primary)
  • Indications Liver metastases
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Apr 2017 New trial record
    • 03 Apr 2017 Results (n=1) published in the Sorrento Therapeutics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top